Efficacy of fish oil supplementation on metabolic dysfunction-associated steatotic liver disease: a meta-analysis
ObjectiveGlobally, the occurrence of Metabolic dysfunction-associated steatotic liver disease (MASLD) is on a steady rise. Fish oil has anti-inflammatory effects and can improve lipid metabolism. The article aims to assess the impact of fish oil supplementation on MASLD.MethodsWe conducted a systema...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Nutrition |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnut.2025.1524830/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832587240597880832 |
|---|---|
| author | Like Zhou Dongmei Sun Houqiao Bai |
| author_facet | Like Zhou Dongmei Sun Houqiao Bai |
| author_sort | Like Zhou |
| collection | DOAJ |
| description | ObjectiveGlobally, the occurrence of Metabolic dysfunction-associated steatotic liver disease (MASLD) is on a steady rise. Fish oil has anti-inflammatory effects and can improve lipid metabolism. The article aims to assess the impact of fish oil supplementation on MASLD.MethodsWe conducted a systematic search of Cochrane, Embase, PubMed, and Web of Science up to September 31, 2024, for randomized control trials (RCTs). The risk of bias of the included RCTs was evaluated using the Cochrane Collaboration’s tool. Outcomes measured were aspects of liver injury, lipid profile, insulin resistance, anthropometric measurements, and more.ResultsSeven randomized controlled trials (RCTs) involving 439 participants were incorporated into the analysis. In general, the risk of bias in these RCTs was either low or not clearly defined. Pooled analysis showed that triglycerides [TG, pooled standard mean difference (SMD): −0.40 (95% CI: −0.58 to −0.21)], aspartate transaminase [AST, SMD: −0.29 (95% CI: −0.48 to −0.10)], HOMA-IR [SMD: −2.06 (95% CI: −3.36 to −0.49)] and waist circumference [Waist-C, SMD: −0.31 (95% CI: −0.54 to −0.08)] were significantly improved. But showed no significant benefits on alanine transaminase [ALT, SMD: −0.15 (95% CI: −0.45 to 0.15)], gamma-glutamyl transpeptidase [GGT, SMD: −0.07 (95% CI: −0.26 to 0.12)], body mass index [BMI, SMD: 0.16 (95% CI: −0.34 to 0.02)], high-density lipoprotein cholesterol [HDL, SMD: 0.02 (95% CI: −0.18 to 0.22)], low-density lipoprotein cholesterol [LDL, SMD: −0.01 (95% CI: −0.20 to 0.18)], Total Cholesterol [TC, SMD: −0.34 (95% CI: −0.70 to 0.01)] and so on.ConclusionThe current evidence supports the fish oil supplementation in improving MASLD. Fish oil supplementation may also regulate blood lipids and improve glucose metabolism disorders.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/#myprospero, identifier CRD42024513246. |
| format | Article |
| id | doaj-art-ae7258eb9baa4bd9be872a41d99bbb7f |
| institution | Kabale University |
| issn | 2296-861X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Nutrition |
| spelling | doaj-art-ae7258eb9baa4bd9be872a41d99bbb7f2025-01-24T16:28:25ZengFrontiers Media S.A.Frontiers in Nutrition2296-861X2025-01-011210.3389/fnut.2025.15248301524830Efficacy of fish oil supplementation on metabolic dysfunction-associated steatotic liver disease: a meta-analysisLike ZhouDongmei SunHouqiao BaiObjectiveGlobally, the occurrence of Metabolic dysfunction-associated steatotic liver disease (MASLD) is on a steady rise. Fish oil has anti-inflammatory effects and can improve lipid metabolism. The article aims to assess the impact of fish oil supplementation on MASLD.MethodsWe conducted a systematic search of Cochrane, Embase, PubMed, and Web of Science up to September 31, 2024, for randomized control trials (RCTs). The risk of bias of the included RCTs was evaluated using the Cochrane Collaboration’s tool. Outcomes measured were aspects of liver injury, lipid profile, insulin resistance, anthropometric measurements, and more.ResultsSeven randomized controlled trials (RCTs) involving 439 participants were incorporated into the analysis. In general, the risk of bias in these RCTs was either low or not clearly defined. Pooled analysis showed that triglycerides [TG, pooled standard mean difference (SMD): −0.40 (95% CI: −0.58 to −0.21)], aspartate transaminase [AST, SMD: −0.29 (95% CI: −0.48 to −0.10)], HOMA-IR [SMD: −2.06 (95% CI: −3.36 to −0.49)] and waist circumference [Waist-C, SMD: −0.31 (95% CI: −0.54 to −0.08)] were significantly improved. But showed no significant benefits on alanine transaminase [ALT, SMD: −0.15 (95% CI: −0.45 to 0.15)], gamma-glutamyl transpeptidase [GGT, SMD: −0.07 (95% CI: −0.26 to 0.12)], body mass index [BMI, SMD: 0.16 (95% CI: −0.34 to 0.02)], high-density lipoprotein cholesterol [HDL, SMD: 0.02 (95% CI: −0.18 to 0.22)], low-density lipoprotein cholesterol [LDL, SMD: −0.01 (95% CI: −0.20 to 0.18)], Total Cholesterol [TC, SMD: −0.34 (95% CI: −0.70 to 0.01)] and so on.ConclusionThe current evidence supports the fish oil supplementation in improving MASLD. Fish oil supplementation may also regulate blood lipids and improve glucose metabolism disorders.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/#myprospero, identifier CRD42024513246.https://www.frontiersin.org/articles/10.3389/fnut.2025.1524830/fullMASLDfish oilmeta-analysisNAFLDNASH |
| spellingShingle | Like Zhou Dongmei Sun Houqiao Bai Efficacy of fish oil supplementation on metabolic dysfunction-associated steatotic liver disease: a meta-analysis Frontiers in Nutrition MASLD fish oil meta-analysis NAFLD NASH |
| title | Efficacy of fish oil supplementation on metabolic dysfunction-associated steatotic liver disease: a meta-analysis |
| title_full | Efficacy of fish oil supplementation on metabolic dysfunction-associated steatotic liver disease: a meta-analysis |
| title_fullStr | Efficacy of fish oil supplementation on metabolic dysfunction-associated steatotic liver disease: a meta-analysis |
| title_full_unstemmed | Efficacy of fish oil supplementation on metabolic dysfunction-associated steatotic liver disease: a meta-analysis |
| title_short | Efficacy of fish oil supplementation on metabolic dysfunction-associated steatotic liver disease: a meta-analysis |
| title_sort | efficacy of fish oil supplementation on metabolic dysfunction associated steatotic liver disease a meta analysis |
| topic | MASLD fish oil meta-analysis NAFLD NASH |
| url | https://www.frontiersin.org/articles/10.3389/fnut.2025.1524830/full |
| work_keys_str_mv | AT likezhou efficacyoffishoilsupplementationonmetabolicdysfunctionassociatedsteatoticliverdiseaseametaanalysis AT dongmeisun efficacyoffishoilsupplementationonmetabolicdysfunctionassociatedsteatoticliverdiseaseametaanalysis AT houqiaobai efficacyoffishoilsupplementationonmetabolicdysfunctionassociatedsteatoticliverdiseaseametaanalysis |